Pharma BD Deal Intelligence
Bayer and Arvinas to collaborate on human PROTAC therapies for cardiovascular, oncological, and gynecological diseases, with >$110M upfront/committed and…
Bayer and Arvinas to develop novel PROTAC candidates for humans and plants in deal worth over $1 billion with JV Oerth Bio
A decrease in revenue from Bayer of $1.1 million related to the termination of the Bayer Collaboration Agreement in August 2024.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
In June 2019, Bayer and Arvinas formed a collaboration to apply Arvinas' PROTAC targeted protein degradation platform to human therapeutics across cardiovascular, oncology, and gynecological disease targets, alongside a separate agricultural PROTAC joint venture (later named Oerth Bio). Per the companies' announcement, Arvinas received an upfront payment plus a direct Bayer equity investment, with total upfront/committed funding across the human collaboration, the equity stake, and the agricultural JV exceeding $110M, and was eligible for more than $685M in development milestones plus royalties. Bayer terminated the human collaboration agreement in August 2024; Arvinas recognized the loss of the associated collaboration revenue and Bayer no longer appears among its named partners.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Arvinas, Inc. (this deal) | 2019 | $1.0B | 59 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
| Bayer AG / Asklepios BioPharmaceuticals | 2020 | $2.0B | 49 |
← Browse all deals · How we score deals
More: 2019 deals · Bayer AG deals · Cardiovascular deals